Precision medicine for cancer with next-generation functional diagnostics

Genome-based cancer therapeutic matching is limited by incomplete biological understanding of the relationship between phenotype and cancer genotype. This Opinion article proposes that this limitation can be addressed by functional testing of live patient tumour cells exposed to potential therapies....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Cancer Jg. 15; H. 12; S. 747 - 756
Hauptverfasser: Friedman, Adam A., Letai, Anthony, Fisher, David E., Flaherty, Keith T.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London Nature Publishing Group UK 01.12.2015
Nature Publishing Group
Schlagworte:
631/154/140
631/208/191
631/208/212/2166
631/67/1059
631/67/69
Biomedicine
Cancer
Cancer Research
Care and treatment
DNA sequencing
Genomics - methods
High-Throughput Nucleotide Sequencing - methods
Humans
Methods
Molecular Diagnostic Techniques - methods
Neoplasms - diagnosis
Neoplasms - genetics
Nucleotide sequencing
Oncology, Experimental
opinion-2
Precision Medicine
ISSN:1474-175X, 1474-1768, 1474-1768
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Genome-based cancer therapeutic matching is limited by incomplete biological understanding of the relationship between phenotype and cancer genotype. This Opinion article proposes that this limitation can be addressed by functional testing of live patient tumour cells exposed to potential therapies. Precision medicine is about matching the right drugs to the right patients. Although this approach is technology agnostic, in cancer there is a tendency to make precision medicine synonymous with genomics. However, genome-based cancer therapeutic matching is limited by incomplete biological understanding of the relationship between phenotype and cancer genotype. This limitation can be addressed by functional testing of live patient tumour cells exposed to potential therapies. Recently, several 'next-generation' functional diagnostic technologies have been reported, including novel methods for tumour manipulation, molecularly precise assays of tumour responses and device-based in situ approaches; these address the limitations of the older generation of chemosensitivity tests. The promise of these new technologies suggests a future diagnostic strategy that integrates functional testing with next-generation sequencing and immunoprofiling to precisely match combination therapies to individual cancer patients.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1474-175X
1474-1768
1474-1768
DOI:10.1038/nrc4015